Netupitant pet imaging and adme studies in humans

Journal of Clinical Pharmacology

Volumn 54, Issue 1, 2014, Pages 97-108

  Spinelli, Tulla ^a   Calcagnile, Selma ^a   Giuliano, Claudio ^a   Rossi, Giorgia ^a   Lanzarotti, Corinna ^a   Mair, Stuart ^b   Stevens, Lloyd ^b   Nisbet, Ian ^b  

^a HELSINN HEALTHCARE SA   (Switzerland)

^b Quotient Clinical Ltd   (United Kingdom)

Author keywords

Metabolism; NEPA; Netupitant; Palonosetron; Receptor occupancy

Indexed keywords

NETUPITANT; NEUROKININ 1 RECEPTOR; PALONOSETRON; UNCLASSIFIED DRUG; VOFOPITANT; VOFOPITANT C11;

ABDOMINAL PAIN; ADULT; ANTERIOR CINGULATE; AREA UNDER THE CURVE; ARTICLE; BRAIN REGION; CONTROLLED STUDY; CORPUS STRIATUM; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG EXCRETION; DRUG METABOLISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FRONTAL CORTEX; HEADACHE; HUMAN; HUMAN EXPERIMENT; LIMIT OF DETECTION; LIVER METABOLISM; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; OCCIPITAL CORTEX; PLASMA CONCENTRATION-TIME CURVE; POSITRON EMISSION TOMOGRAPHY; RADIOACTIVITY; RANDOMIZED CONTROLLED TRIAL; RECEPTOR OCCUPANCY; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; YOUNG ADULT;

METABOLISM; NEPA; NETUPITANT; PALONOSETRON; RECEPTOR OCCUPANCY;

ADULT; AREA UNDER CURVE; BILE; BIOLOGICAL MARKERS; DRUG COMBINATIONS; HUMANS; ISOQUINOLINES; KIDNEY; LIVER; MALE; MIDDLE AGED; NEUROKININ-1 RECEPTOR ANTAGONISTS; PIPERIDINES; POSITRON-EMISSION TOMOGRAPHY; PYRIDINES; QUINUCLIDINES; RADIOPHARMACEUTICALS; SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS; TETRAZOLES; TISSUE DISTRIBUTION; YOUNG ADULT;

EID: 84893250849     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.198     Document Type: Article

References (40)

1. Sun CC, Bodurka DC, Weaver CB, et al. Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer. 2005;13(4):219-227
2. Feyer P, Jordan K. Update and new trends in antiemetic therapy: the continuing need for novel therapies. Ann Oncol. 2011;22(1): 30-38
3. Schwartzberg L. Chemotherapy-induced nausea and vomiting: state of the art in 2006. J Support Oncol. 2006;4(2 Suppl 1):3-8
4. Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol. 2006;24(27):4472-4478
5. Jordan K, Sippel C, Schmoll HJ. Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations. Oncologist. 2007;12(9):1143-1150
6. Hesketh PJ, Van Belle S, Aapro M, et al. Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer. 2003;39(8):1074-1080
7. Rubenstein EB, Slusher BS, Rojas C, Navari RM. New approaches to chemotherapy-induced nausea and vomiting: from neuropharmacology to clinical investigations. Cancer J. 2006;12(5): 341-347.
8. Roila F, Herrstedt J, Aapro M, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy and radiotherapyinduced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol. 2010;21(Suppl 5):v232-v243. www.mascc. Org
9. Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2011;29(31):4189-4198. www.asco.org
10. NCCN Clinical Practice Guidelines in Oncology: Antiemesis Version 1. 2014; www.nccn.org
11. Cohen L, de Moor CA, Eisenberg P, Ming EE, Hu H. Chemotherapy- induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer. 2007;15(5):497-503. Epub 2006 Nov. 14
12. Roscoe JA, Morrow GR, Hickok JT, Mustian KM, Shelke AR. Biobehavioral factors in chemotherapy-induced nausea and vomiting. J Natl Compr Canc Netw. 2004;2(5):501-508. Review
13. Salsman JM, Grunberg SM, Beaumont JL, et al. Communicating about chemotherapy-induced nausea and vomiting: a comparison of patient and provider perspectives. J Natl Compr Canc Netw. 2012;10(2):149-157
14. Rizzi A, Campi B, Camarda V, et al. In vitro and in vivo pharmacological characterization of the novel NK(1) receptor selective antagonist Netupitant. Peptides. 2010;37(1):86-97
15. Gralla R, Lichinitser M, Van Der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a doubleblind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol. 2003;14(10):1570- 1577
16. Eisenberg P, Figueroa-Vadillo J, Zamora R, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer. 2003;98(11):2473-2482.
17. Saito M, Aogi K, Sekine I, et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol. 2009;10(2):115-124. Epub 2009 Jan. 8. Erratum in: Lancet Oncol. 2010;11(3):226
18. Aapro MS, Grunberg SM, Manikhas GM, et al. A phase III, doubleblind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol. 2006;17(9):1441- 1449
19. Rojas C, Li Y, Zhang J, et al. The antiemetic 5-HT3 receptor antagonist Palonosetron inhibits substance P-mediated responses in vitro and in vivo. J Pharmacol Exp Ther. 2010;335(2):362-368.Epub 2010 Aug. 19
20. Rojas C, Slusher BS. Pharmacological mechanism of 5-HT3 and tachykinin NK-1 receptor antagonism to prevent chemotherapyinduced nausea and vomiting. Eur J Pharmacol. 2012;684(1-3):1- 7. Epub 2012 Mar. 9
21. Stathis M, Pietra C, Rojas C, Slusher BS. Inhibition of substance Pmediated responses in NG 108-15 cells by netupitant and palonosetron exhibit synergistic effects. Eur J Pharmacol. 2012;689(1-3):25-30
22. Gardner CJ, Armour DR, Beattie DT, et al. GR205171: a novel antagonist with high affinity for the tachykinin NK1 receptor, and potent broad-spectrum anti-emetic activity. Regul Pept. 1996;65(1):45-53
23. Bergström M, Fasth K-J, Kilpatrick G, et al. Brain uptake and receptor binding of two [11C]-labelled high affinity NK1 antagonists, GR203040 and GR205171 - PET studies in rhesus monkey. Neuropharmacology. 2000;39(4):664-670
24. Michelgård A, Appel L, Pissiota A, et al. Symptom provocation in specific phobia affects the substance P neurokinin-1 receptor system. Biol Psychiatry. 2007;61(8):1002- 1006. Epub 2006 Sept. 1
25. Solin O, Eskola O, Hamill TG, et al. Synthesis and characterization of a potent, selective, radiolabeled substance-P antagonist for NK1 receptor quantitation: ([18F]SPA-RQ). Mol Imaging Biol. 2004;6(6):373-384
26. Bergström M, Hargreaves RJ, Burns DH, et al. Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant. Biol Psychiatry. 2004;55:1007-1012
27. Hietala J, Nyman MJ, Eskola O, et al. Visualization and quantification of neurokinin-1 (NK1) receptors in the human brain. Mol Imaging Biol. 2005;7(4):262-272.
28. Nyman MJ, Eskola O, Kajander J, et al. Gender and age affect NK1 receptors in the human brain - a positron emission tomography study with [18F]SPA-RQ. Int J Neuropsychopharmacol. 2007;10(2):219-229. Epub 2006 Mar. 30
29. Andersson JLR. A rapid and accurate method to realign PET scans utilizing image edge transformation. J Nucl Med. 1995;36:657- 669
30. Patlak CS, Blasberg R. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab. 1985;5:584-590
31. Wolfensberger SPA, van Berckel BNM, Airaksinen AJ, et al. First evaluation of [11C]R116301 as an in vivo tracer of NK1 receptors in man. Mol Imaging Biol. 2009;11(4):241-245
32. Van Laer K, De Hoon J, Bormans G, et al. Equivalent dyanamic human brain NK-1 receptor occupancy following single-dose IV fosaprepitant vs. oral aprepitant as assessed by PET imaging. Clin Pharmacol Ther. 2012;92(2):243-250
33. Helsinn Internal Report: Determination of Netupitant and Its Metabolites, M1, M2, and M3 Concentrations in Human Plasma and Urine Samples from Study NETU-09-21, December 2011
34. Caberlotto L, Hurd YL, Murdock P, et al. Neurokinin 1 receptor and relative abundance of the short and long isoforms in human brain. Eur J Neurosci. 2003;17:1736- 1746
35. Hargreaves R. Imaging substance P receptors (NK1) in the living human brain using positron emission tomography. J Clin Psychiatry. 2002;63(Suppl 11):18-24
36. Keller M, Montgomery S, Ball W, et al. Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol Psychiatry. 2006;59(3): 216-223. Epub 2005 Oct. 24
37. Hesketh P, Rossi G, Rizzi G, et al. Efficacy of NEPA, a novel combination of netupitant (NETU) and palonosetron (PALO), for prevention of chemotherapy-induced nausea and vomiting (CINV) following highly emetogenic chemotherapy (HEC). J Clin Oncol.2013;31 (suppl; abstr 9512J)
38. Aapro M, Rossi G, Rizzi G, Palmas M, Grunberg S. Phase 3 study of NEPA, a fixed-dose combination of netupitant (NETU) and palonosetron (PALO), versus PALO for prevention of chemotherapy- induced nausea and vomiting (CINV) following moderately emetogenic chemotherapy (MEC). J.Clin Oncol. 2013;31 (suppl; abstr LBA9514)
39. Jordan K, Rossi G, Rizzi G, Palmas M, Gralla RJ. NEPA, a fixeddose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting (CINV) following repeated chemotherapy cycles: Results of a phase 3 trial. J Clin Oncol. 2013;31 (suppl; abstr e20716)
40. Zamuner S, Rabiner EA, Fernandes SA, et al. A pharmacokinetic PET study of NK1 receptor occupancy. Eur J Nucl Med Mol Imaging. 2012;39(2):226-235. Epub 2011 Oct. 13